CLBS Projected Dividend Yield
Caladrius Biosciences Inc ( NASDAQ : CLBS )Caladrius Biosciences is a clinical-stage biopharmaceutical company focused on the development of treatments and reversal of severe diseases. Co.'s product candidates include: XOWNA®, which is a Phase 2a study and an ongoing follow-on Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction; HONEDRA®, which is eligible for early conditional approval in Japan for the treatment of critical limb ischemia based on the results of a clinical trial; and CLBS201, which is designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with chronic kidney disease related to type 2 diabetes. 20 YEAR PERFORMANCE RESULTS |
CLBS Dividend History Detail CLBS Dividend News CLBS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |